Sichuan Biopharmaceutical Industry Group
四川生物医药产业集团
Sichuan Biopharmaceutical Industry Group (四川生物医药产业集团) appears in elsewhere's corpus only as an investor: it was a continuing backer ("持续投资") in Chengdu-based Zenitar Biopharma's nearly RMB 400 million Series B+ round in August 2025, a round led by Qiming Venture Partners with Gaorong, Jifeng, 5Y Capital and others following . That points to a Sichuan-based, state-flavored biopharma industry investor, but elsewhere's corpus does not carry a standalone profile of the group itself — its founding, AUM, mandate or other portfolio moves aren't covered, so beyond its role in that one deal there's little more to say here.
AI-generated — may contain errors, please verify.
Coverage
5Y News | Zai Ling Bio Completes Nearly RMB 400 Million Series B+ Round
Accelerating the buildout of an innovative drug pipeline built on differentiated molecular scaffolds and novel targets, with a commitment to addressing unmet clinical needs.
Zenitar Closes Nearly RMB 400 Million Series B+ Round, Multiple Global First-in-Class Drugs Enter Pivotal Clinical Trials
Structural Biology and AI-Driven Innovative Drug Discovery and Development
Zenitar Raises Nearly 400 Million Yuan in B+ Round Led by Qiming Venture Partners
Zenitar is a structure-based biology and AI-driven innovative drug R&D company, focused on unmet clinical needs in major therapeutic areas including oncology, autoimmune diseases, inflammation, and neurological disorders. The company is dedicated to discovering, developing, and commercializing first-in-class and best-in-class innovative medicines.
